PriceTargets.com logo

Ayala Pharmaceuticals - ADXS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.03 As of 12/20/2024 04:31 PM ET
+0 (0.00%)

This chart shows the closing price for ADXS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ayala Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADXS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Ayala Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.03.

This chart shows the closing price for ADXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Ayala Pharmaceuticals. This rating has held steady since October 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/16/2023LADENBURG THALM/SH SHReiterated RatingBuy ➝ Neutral
5/30/2023LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy
4/19/2021Alliance Global PartnersLower TargetBuy$5.00 ➝ $2.25
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Ayala Pharmaceuticals logo
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Read More

Today's Range

Now: $0.03
Low: $0.03
High: $0.03

50 Day Range

MA: $0.04
Low: $0.03
High: $0.11

52 Week Range

Now: $0.03
Low: $0.00
High: $1.49

Volume

738 shs

Average Volume

11,887 shs

Market Capitalization

$1.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Ayala Pharmaceuticals?

The following Wall Street analysts have issued research reports on Ayala Pharmaceuticals in the last year: StockNews.com.
View the latest analyst ratings for ADXS.

What is the current price target for Ayala Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Ayala Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Ayala Pharmaceuticals in the next year.
View the latest price targets for ADXS.

What is the current consensus analyst rating for Ayala Pharmaceuticals?

Ayala Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ADXS.

What other companies compete with Ayala Pharmaceuticals?

Other companies that are similar to Ayala Pharmaceuticals include Lixte Biotechnology, Aditxt, Fresh Tracks Therapeutics, Creative Medical Technology and Oragenics. Learn More about companies similar to Ayala Pharmaceuticals.

How do I contact Ayala Pharmaceuticals' investor relations team?

Ayala Pharmaceuticals' physical mailing address is 9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ 08852, United States. The company's listed phone number is 609-452-9813 and its investor relations email address is [email protected]. The official website for Ayala Pharmaceuticals is www.ayalapharma.com. Learn More about contacing Ayala Pharmaceuticals investor relations.